The LINC 3 extension study, by Maria Fleseriu and team, suggests that long-term treatment with osilodrostat is associated with sustained benefits for people with Cushing’s disease.
Findings from two studies highlight that mortality rates are elevated among patients with Cushing’s syndrome compared with healthy individuals, and this increased risk is attenuated, but still significant, in those who have achieved remission.
Treatment with the 11β-hydroxylase inhibitor osilodrostat normalizes cortisol levels in the majority of patients with Cushing’s disease, report Mônica Gadelha and co-investigators from the LINC 4 trial.
To coincide with the first anniversary of Cushing’s Hub, the Editorial Board launches the Clinical Case Competition, 28 February 2022, Rare Disease Day.
People with benign adrenal tumors and mild autonomous cortisol secretion have an increased burden of cardiometabolic disease similar to that seen in Cushing’s syndrome, suggest ENSAT EURINE-ACT study results.
Matthias Kroiss and colleagues outline the clinical characteristics, treatment, and outcomes of patients with the rare condition of ectopic Cushing’s syndrome associated with advanced medullary thyroid cancer.
Maria Fleseriu and colleagues from 13 countries across five continents have developed updated consensus recommendations for the diagnosis and management of Cushing’s disease, which were published online in The Lancet Diabetes & Endocrinology in October 2021.
The 7th ENEA Virtual Workshop will provide an opportunity for delegates to hear about the latest findings on Cushing’s disease from internationally renowned experts.
Using strict biochemical thresholds for the diagnosis of patients with suspected Cushing’s disease could help improve diagnostic accuracy, report Daniel Kelly and co-authors.
The selective glucocorticoid receptor modulator relacorilant may warrant further investigation for the treatment of endogenous Cushing’s syndrome, suggest phase 2 trial results published in Frontiers in Endocrinology in July 2021.
The 37th Congress of the Société Française d’Endocrinologie – the French Society of Endocrinology – will be held in Le Havre in October 2021.
The 2021 SfE BES is to be held at the Edinburgh International Conference Centre between 8 to 10 November 2021 with ‘on demand’ streaming services for delegates who are unable to attend in person.
Bone mineral density continues to improve for up to 20 years after treatment for Cushing’s syndrome, report Annenienke van de Ven and team.
Study findings from Martin Reincke and colleagues suggest that serum IGF-I levels 6 months after curative surgery for endogenous Cushing’s syndrome may be predictive of long-term muscle strength outcomes.
Regular biochemical screening, rather than relying on clinical signs and symptoms, is associated with earlier detection of recurrent Cushing’s disease, suggests research from Martin Reincke and colleagues.
The eECE presents a wide variety of engaging events ranging from plenary and award lectures, and symposia, to ‘Meet the Expert’ sessions, new scientific sessions and debates.
Having hyper- or hypocortisolism at the time of pregnancy may increase the risk for preterm birth and other pregnancy complications among women with a history of Cushing’s disease, indicate findings from the Baby-Cush study.
The next major event in the calendar is the Endocrine Society's ENDO2021 meeting, which is being held virtually via a state-of-the-art digital platform.
Research from Daniel Bengtsson and team suggests that people with Cushing’s disease have higher rates of psychotropic drug use than those without, both before the time of diagnosis and later in the disease course.
A substantial proportion of people with Cushing’s syndrome have abnormal thyroid function related to cortisol exposure, and this is reversible after curative surgery, study findings suggest.
The 19th International Congress of Endocrinology (ICE 2021) will be held over 5 days at the end of February 2021 in a completely virtual format. With an excellent scientific program this innovative and interactive event will include top-level presentations from endocrinology experts around the world.
The last day of February is international Rare Disease Day. In 2021, it’s on Sunday 28 February.
The main aim of the day is to raise aware of rare disease within the general public, but also among policy makers, public authorities, industry representatives, researchers, and healthcare professionals.